631 related articles for article (PubMed ID: 20941354)
1. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.
Mansfield BE; Oltean HN; Oliver BG; Hoot SJ; Leyde SE; Hedstrom L; White TC
PLoS Pathog; 2010 Sep; 6(9):e1001126. PubMed ID: 20941354
[TBL] [Abstract][Full Text] [Related]
2. Azole drug import into the pathogenic fungus Aspergillus fumigatus.
Esquivel BD; Smith AR; Zavrel M; White TC
Antimicrob Agents Chemother; 2015; 59(6):3390-8. PubMed ID: 25824209
[TBL] [Abstract][Full Text] [Related]
3. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.
Holmes AR; Lin YH; Niimi K; Lamping E; Keniya M; Niimi M; Tanabe K; Monk BC; Cannon RD
Antimicrob Agents Chemother; 2008 Nov; 52(11):3851-62. PubMed ID: 18710914
[TBL] [Abstract][Full Text] [Related]
4. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.
Holmes AR; Keniya MV; Ivnitski-Steele I; Monk BC; Lamping E; Sklar LA; Cannon RD
Antimicrob Agents Chemother; 2012 Mar; 56(3):1508-15. PubMed ID: 22203607
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenic
Kane A; Dinh H; Campbell L; Cain AK; Hibbs D; Carter D
Microbiol Spectr; 2024 Jun; 12(6):e0012124. PubMed ID: 38695556
[TBL] [Abstract][Full Text] [Related]
6. Cryptococcus neoformans, Unlike Candida albicans, Forms Aneuploid Clones Directly from Uninucleated Cells under Fluconazole Stress.
Chang YC; Khanal Lamichhane A; Kwon-Chung KJ
mBio; 2018 Dec; 9(6):. PubMed ID: 30514783
[TBL] [Abstract][Full Text] [Related]
7. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.
Sanglard D; Kuchler K; Ischer F; Pagani JL; Monod M; Bille J
Antimicrob Agents Chemother; 1995 Nov; 39(11):2378-86. PubMed ID: 8585712
[TBL] [Abstract][Full Text] [Related]
9. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
Sionov E; Chang YC; Garraffo HM; Kwon-Chung KJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2804-15. PubMed ID: 19414582
[TBL] [Abstract][Full Text] [Related]
10. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
11. Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
Lamping E; Ranchod A; Nakamura K; Tyndall JD; Niimi K; Holmes AR; Niimi M; Cannon RD
Antimicrob Agents Chemother; 2009 Feb; 53(2):354-69. PubMed ID: 19015352
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.
Sionov E; Lee H; Chang YC; Kwon-Chung KJ
PLoS Pathog; 2010 Apr; 6(4):e1000848. PubMed ID: 20368972
[TBL] [Abstract][Full Text] [Related]
13. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
Basso LR; Gast CE; Bruzual I; Wong B
J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
[TBL] [Abstract][Full Text] [Related]
14. Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance.
Monk BC; Niimi K; Lin S; Knight A; Kardos TB; Cannon RD; Parshot R; King A; Lun D; Harding DR
Antimicrob Agents Chemother; 2005 Jan; 49(1):57-70. PubMed ID: 15616276
[TBL] [Abstract][Full Text] [Related]
15. Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-Resistant
Xu J; Liu R; Sun F; An L; Shang Z; Kong L; Yang M
Front Cell Infect Microbiol; 2019; 9():211. PubMed ID: 31281800
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India.
Mane A; Vidhate P; Kusro C; Waman V; Saxena V; Kulkarni-Kale U; Risbud A
Mycoses; 2016 Feb; 59(2):93-100. PubMed ID: 26648048
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
[TBL] [Abstract][Full Text] [Related]
18. Coregulation of extracellular vesicle production and fluconazole susceptibility in
Rizzo J; Trottier A; Moyrand F; Coppée JY; Maufrais C; Zimbres ACG; Dang TTV; Alanio A; Desnos-Ollivier M; Mouyna I; Péhau-Arnaude G; Commere PH; Novault S; Ene IV; Nimrichter L; Rodrigues ML; Janbon G
mBio; 2023 Aug; 14(4):e0087023. PubMed ID: 37310732
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
Zhou J; Li J; Cheong I; Liu NN; Wang H
Bioorg Med Chem; 2021 Aug; 44():116293. PubMed ID: 34243044
[TBL] [Abstract][Full Text] [Related]
20. The synergistic antifungal effects of gypenosides combined with fluconazole against resistant Candida albicans via inhibiting the drug efflux and biofilm formation.
Liu Y; Ren H; Wang D; Zhang M; Sun S; Zhao Y
Biomed Pharmacother; 2020 Oct; 130():110580. PubMed ID: 32745913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
